Literature DB >> 17878386

Deficiency of the NF-kappaB inhibitor caspase activating and recruitment domain 8 in patients with rheumatoid arthritis is associated with disease severity.

Ana Fontalba1, Victor Martinez-Taboada, Olga Gutierrez, Carlos Pipaon, Natividad Benito, Alejandro Balsa, Ricardo Blanco, Jose L Fernandez-Luna.   

Abstract

Caspase activating and recruitment domain 8 (CARD8) potently inhibits NF-kappaB signaling, which plays a key role in inflammation, and may contribute to avoid a pathologic activation of NF-kappaB; however, the transcriptional mechanisms regulating CARD8 expression and the relevance of this protein in inflammatory diseases are poorly understood. We found a NF-kappaB-binding element within the human CARD8 promoter that was required for transcriptional activity in response to TNF-alpha and the p65 subunit of NF-kappaB. Moreover, TNF-alpha and overexpression of p65 induced the formation of NF-kappaB-CARD8 promoter complexes. Thus, CARD8 may control NF-kappaB activation through a regulatory loop. To study the relevance of CARD8 in chronic inflammatory disorders, we functionally characterized a deleterious polymorphism (p.C10X) and studied its association with rheumatoid arthritis (RA). Transfection of cell lines with the allelic variants of CARD8 revealed that full-length (CARD8-L) but not truncated (CARD8-S) protein inhibits NF-kappaB transcriptional activity, and abrogates the binding of NF-kappaB to its consensus site. Furthermore, in contrast to the full-length protein, CARD8-S did not modify the expression of NF-kappaB target genes (cIAP, A1), in response to TNF-alpha. We analyzed the p.C10X polymorphism in 200 patients with RA, and found that homozygous carriers of the CARD8-S allele have higher disease activity score (p = 0.014), more extra-articular manifestations (p = 0.03), and a lower probability of clinical remission (p = 0.03) than the CARD8-L allele carriers. Overall, our findings provide molecular insight into the expression of CARD8 by NF-kappaB, and suggest that a deleterious polymorphism of CARD8 may help predict the severity of RA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17878386     DOI: 10.4049/jimmunol.179.7.4867

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Gene-gene interaction between CARD8 and interleukin-6 reduces Alzheimer's disease risk.

Authors:  Ana Fontalba; Olga Gutiérrez; Javier Llorca; Ignacio Mateo; José Luis Vázquez-Higuera; José Berciano; José Luis Fernández-Luna; Onofre Combarros
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

2.  Genetic variation in inflammasome genes is associated with outcome in bacterial meningitis.

Authors:  Madelijn Geldhoff; Barry B Mook-Kanamori; Matthijs C Brouwer; Mercedes Valls Seron; Frank Baas; Arie van der Ende; Diederik van de Beek
Journal:  Immunogenetics       Date:  2012-09-30       Impact factor: 2.846

3.  Polymorphisms and expression of inflammasome genes are associated with the development and severity of rheumatoid arthritis in Brazilian patients.

Authors:  Catarina Addobbati; Heidi Lacerda Alves da Cruz; José Eduardo Adelino; Amanda Luíze Melo Tavares Ramos; Thiago Sotero Fragoso; Alexandre Domingues; Ângela Luiza Branco Pinto Duarte; Renê Donizeti Ribeiro Oliveira; Paulo Louzada-Júnior; Eduardo Antônio Donadi; Alessandra Pontillo; Jaqueline de Azevêdo Silva; Sergio Crovella; Paula Sandrin-Garcia
Journal:  Inflamm Res       Date:  2017-12-11       Impact factor: 4.575

4.  A genome-wide in vitro bacterial-infection screen reveals human variation in the host response associated with inflammatory disease.

Authors:  Dennis C Ko; Kajal P Shukla; Christine Fong; Michael Wasnick; Mitchell J Brittnacher; Mark M Wurfel; Tarah D Holden; Grant E O'Keefe; Brian Van Yserloo; Joshua M Akey; Samuel I Miller
Journal:  Am J Hum Genet       Date:  2009-08-06       Impact factor: 11.025

5.  Effective treatment of rat adjuvant-induced arthritis by celastrol.

Authors:  R Cascão; B Vidal; H Raquel; A Neves-Costa; N Figueiredo; V Gupta; J E Fonseca; L F Moita
Journal:  Autoimmun Rev       Date:  2012-03-03       Impact factor: 9.754

Review 6.  Targeting inflammasomes in rheumatic diseases.

Authors:  Alexander So; Annette Ives; Leo A B Joosten; Nathalie Busso
Journal:  Nat Rev Rheumatol       Date:  2013-05-14       Impact factor: 20.543

7.  Functional genetic screen of human diversity reveals that a methionine salvage enzyme regulates inflammatory cell death.

Authors:  Dennis C Ko; Eric R Gamazon; Kajal P Shukla; Richard A Pfuetzner; Dale Whittington; Tarah D Holden; Mitchell J Brittnacher; Christine Fong; Matthew Radey; Cassandra Ogohara; Amy L Stark; Joshua M Akey; M Eileen Dolan; Mark M Wurfel; Samuel I Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-25       Impact factor: 11.205

8.  CARD8 rs2043211 (p.C10X) polymorphism is not associated with disease susceptibility or cardiovascular events in Spanish rheumatoid arthritis patients.

Authors:  Mercedes García-Bermúdez; Raquel López-Mejías; Carlos González-Juanatey; Alfonso Corrales; Santos Castañeda; Ana M Ortiz; José A Miranda-Filloy; Carmen Gómez-Vaquero; Benjamín Fernández-Gutiérrez; Alejandro Balsa; Dora Pascual-Salcedo; Ricardo Blanco; Javier Llorca; Javier Martín; Miguel A González-Gay
Journal:  DNA Cell Biol       Date:  2012-10-22       Impact factor: 3.311

9.  The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1β and IL-18 production.

Authors:  Deepti Verma; Eva Särndahl; Henrik Andersson; Per Eriksson; Mats Fredrikson; Jan-Ingvar Jönsson; Maria Lerm; Peter Söderkvist
Journal:  PLoS One       Date:  2012-04-17       Impact factor: 3.240

10.  NLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseases.

Authors:  Alenka Franko; Katja Goricar; Viljem Kovac; Metoda Dodic-Fikfak; Vita Dolzan
Journal:  J Med Biochem       Date:  2020-01-10       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.